Company intelligence / Profile preview

MoonLake Immunotherapeutics

Ownership: Public · MLTX
Development stage: Phase 3

Overview

MoonLake Immunotherapeutics has advanced its lead asset, sonelokimab—a novel investigational Nanobody® targeting all relevant IL‑17 dimers—into multiple late-stage clinical trials. The company’s VELA Phase III program in hidradenitis suppurativa has completed patient recruitment with a primary endpoint readout expected soon. Interim results from the LEDA Phase II study in palmoplantar pustulosis have been reported earlier than anticipated, further de-risking development. Across eight active clinical trials, sonelokimab continues to show promise for inflammatory diseases with high unmet need.

Therapeutic areas: DermatologyRheumatology
Modalities: Nanobodies® (single-domain antibodies)Antibodies (specifically, humanized nanobodies)
Industry: Biotech

Drug pipeline

2 assets

sonelokimab

1 more asset in the full pipeline.

Request access →

Partnerships

Hercules Capital Inc. — up to $500 million non-dilutive financing agreement for growth and launch activities. No major pharma co-development partnerships disclosed.

Financials

Market cap: $1.2B
Total revenue: $0
Enterprise value: $718.6M

Beyond the preview

Go deeper on MoonLake Immunotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MoonLake Immunotherapeutics.

Explore the full profile